{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:50:22Z","timestamp":1787061022849,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00415-025-13049-5","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:29:26Z","timestamp":1743892166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Biological frameworks for Parkinson\u2019s disease: the heterogeneity SAAgged"],"prefix":"10.1007","volume":"272","author":[{"given":"Annamaria","family":"Landolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-7419","authenticated-orcid":false,"given":"Roberto","family":"Erro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"13049_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/BF01276421","volume":"103","author":"H Braak","year":"1996","unstructured":"Braak H, Braak E, Yilmazer D et al (1996) (1996) Pattern of brain destruction in Parkinson\u2019s and Alzheimer\u2019s diseases. J Neural Transm Vienna Austria 103:455\u2013490. https:\/\/doi.org\/10.1007\/BF01276421","journal-title":"J Neural Transm Vienna Austria"},{"key":"13049_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA et al (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med 14:504\u2013506. https:\/\/doi.org\/10.1038\/nm1747","journal-title":"Nat Med"},{"key":"13049_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J et al (2012) Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949\u2013953. https:\/\/doi.org\/10.1126\/science.1227157","journal-title":"Science"},{"key":"13049_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D et al (2024) A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 23:191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0","journal-title":"Lancet Neurol"},{"key":"13049_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K et al (2024) A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol 23:178\u2013190. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2","journal-title":"Lancet Neurol"},{"key":"13049_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30007","author":"LV Kalia","year":"2024","unstructured":"Kalia LV, Berg D, Kordower JH et al (2024) International Parkinson and movement disorder society viewpoint on biological frameworks of Parkinson\u2019s disease: current status and future directions. Mov Disord. https:\/\/doi.org\/10.1002\/mds.30007","journal-title":"Mov Disord"},{"key":"13049_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/jamaneurol.2024.2381","volume":"81","author":"HR Morris","year":"2024","unstructured":"Morris HR, Lees AJ (2024) Limitations of the \u03b1-synuclein seed amplification assay in clinical practice: understanding the pathological diversity of Parkinson Syndrome. JAMA Neurol 81:905\u2013906. https:\/\/doi.org\/10.1001\/jamaneurol.2024.2381","journal-title":"JAMA Neurol"},{"key":"13049_CR8","doi-asserted-by":"publisher","first-page":"106041","DOI":"10.1016\/j.parkreldis.2024.106041","volume":"122","author":"E Mulroy","year":"2024","unstructured":"Mulroy E, Erro R, Bhatia KP, Hallett M (2024) Refining the clinical diagnosis of Parkinson\u2019s disease. Parkinsonism Relat Disord 122:106041. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106041","journal-title":"Parkinsonism Relat Disord"},{"key":"13049_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1474-4422(24)00225-4","volume":"23","author":"JG Goldman","year":"2024","unstructured":"Goldman JG, Boeve BF, Galasko D et al (2024) Concerns with the new biological research criteria for synucleinopathy. Lancet Neurol 23:660\u2013661. https:\/\/doi.org\/10.1016\/S1474-4422(24)00225-4","journal-title":"Lancet Neurol"},{"key":"13049_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/mds.29419","volume":"38","author":"TF Outeiro","year":"2023","unstructured":"Outeiro TF, Alcalay RN, Antonini A et al (2023) Defining the riddle in order to solve it: there is more than one \u201cParkinson\u2019s disease.\u201d Mov Disord Off J Mov Disord Soc 38:1127\u20131142. https:\/\/doi.org\/10.1002\/mds.29419","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"13049_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/wnl.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, McDermott M, Carter J et al (1990) Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort The Parkinson Study Group. Neurology 40:1529\u20131534. https:\/\/doi.org\/10.1212\/wnl.40.10.1529","journal-title":"Neurology"},{"key":"13049_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","volume":"17","author":"D Berg","year":"2021","unstructured":"Berg D, Borghammer P, Fereshtehnejad S-M et al (2021) Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol 17:349\u2013361. https:\/\/doi.org\/10.1038\/s41582-021-00486-9","journal-title":"Nat Rev Neurol"},{"issue":"Pt 11","key":"13049_CR13","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/brain\/awp234","volume":"132","author":"M Selikhova","year":"2009","unstructured":"Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson\u2019s disease. Brain 132(Pt 11):2947\u20132957","journal-title":"Brain"},{"key":"13049_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","volume":"76","author":"E De Pablo-Fern\u00e1ndez","year":"2019","unstructured":"De Pablo-Fern\u00e1ndez E, Lees AJ, Holton JL, Warner TT (2019) Prognosis and Neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76:470\u2013479. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4377","journal-title":"JAMA Neurol"},{"key":"13049_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/archneurol.2010.79","volume":"67","author":"JC D\u00e4chsel","year":"2010","unstructured":"D\u00e4chsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. Arch Neurol 67:542\u2013547. https:\/\/doi.org\/10.1001\/archneurol.2010.79","journal-title":"Arch Neurol"},{"key":"13049_CR16","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/mds.27527","volume":"33","author":"J Trinh","year":"2018","unstructured":"Trinh J, Zeldenrust FMJ, Huang J et al (2018) Genotype-phenotype relations for the Parkinson\u2019s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord Off J Mov Disord Soc 33:1857\u20131870. https:\/\/doi.org\/10.1002\/mds.27527","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"13049_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mdc3.14146","volume":"11","author":"C Sorrentino","year":"2024","unstructured":"Sorrentino C, Dati G, Cuoco S et al (2024) Expanding the spectrum of GBA1-associated neurodegenerative diseases in an Italian family. Mov Disord Clin Pract 11:1030\u20131034. https:\/\/doi.org\/10.1002\/mdc3.14146","journal-title":"Mov Disord Clin Pract"},{"key":"13049_CR18","doi-asserted-by":"publisher","first-page":"105401","DOI":"10.1016\/j.parkreldis.2023.105401","volume":"111","author":"Y Bakhit","year":"2023","unstructured":"Bakhit Y, Ibrahim MO, Tesson C et al (2023) Intrafamilial and interfamilial heterogeneity of PINK1-associated Parkinson\u2019s disease in Sudan. Parkinsonism Relat Disord 111:105401. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105401","journal-title":"Parkinsonism Relat Disord"},{"key":"13049_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.20753","volume":"59","author":"K Nishioka","year":"2006","unstructured":"Nishioka K, Hayashi S, Farrer MJ et al (2006) Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson\u2019s disease. Ann Neurol 59:298\u2013309. https:\/\/doi.org\/10.1002\/ana.20753","journal-title":"Ann Neurol"},{"key":"13049_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa120","author":"JL Lowry","year":"2020","unstructured":"Lowry JL, Ryan \u00c9B, Esengul YT et al (2020) Intricacies of aetiology in intrafamilial degenerative disease. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcaa120","journal-title":"Brain Commun"},{"key":"13049_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JPD-230376","volume":"14","author":"S-Y Lim","year":"2024","unstructured":"Lim S-Y, Klein C (2024) Parkinson\u2019s disease is predominantly a genetic disease. J Park Dis 14:467\u2013482. https:\/\/doi.org\/10.3233\/JPD-230376","journal-title":"J Park Dis"},{"key":"13049_CR22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/mds.29698","volume":"39","author":"J-A Tunold","year":"2024","unstructured":"Tunold J-A, Tan MMX, Toft M et al (2024) Lysosomal polygenic burden drives cognitive decline in Parkinson\u2019s disease with low Alzheimer risk. Mov Disord Off J Mov Disord Soc 39:596\u2013601. https:\/\/doi.org\/10.1002\/mds.29698","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"13049_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/ana.26416","volume":"92","author":"H Liu","year":"2022","unstructured":"Liu H, Dehestani M, Blauwendraat C et al (2022) Polygenic resilience modulates the penetrance of Parkinson disease genetic risk factors. Ann Neurol 92:270\u2013278. https:\/\/doi.org\/10.1002\/ana.26416","journal-title":"Ann Neurol"},{"key":"13049_CR24","doi-asserted-by":"publisher","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","volume":"90","author":"G Pagano","year":"2018","unstructured":"Pagano G, Polychronis S, Wilson H et al (2018) Diabetes mellitus and Parkinson disease. Neurology 90:e1654\u2013e1662. https:\/\/doi.org\/10.1212\/WNL.0000000000005475","journal-title":"Neurology"},{"key":"13049_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.parkreldis.2013.01.016","volume":"19","author":"V Kotagal","year":"2013","unstructured":"Kotagal V, Albin RL, M\u00fcller MLTM et al (2013) Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 19:522\u2013526. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.01.016","journal-title":"Parkinsonism Relat Disord"},{"key":"13049_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29992","author":"H Tang","year":"2024","unstructured":"Tang H, Lu Y, Okun MS et al (2024) Glucagon-like peptide-1 receptor agonists and risk of Parkinson\u2019s disease in patients with type 2 diabetes: a population-based cohort study. Mov Disord Off J Mov Disord Soc. https:\/\/doi.org\/10.1002\/mds.29992","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"13049_CR27","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1212\/WNL.0000000000000356","volume":"82","author":"V Kotagal","year":"2014","unstructured":"Kotagal V, Albin RL, M\u00fcller MLTM et al (2014) Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 82:1514\u20131520. https:\/\/doi.org\/10.1212\/WNL.0000000000000356","journal-title":"Neurology"},{"key":"13049_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jns.2016.06.015","volume":"367","author":"M Moccia","year":"2016","unstructured":"Moccia M, Tedeschi E, Ugga L et al (2016) White matter changes and the development of motor phenotypes in de novo Parkinson\u2019s Disease. J Neurol Sci 367:215\u2013219. https:\/\/doi.org\/10.1016\/j.jns.2016.06.015","journal-title":"J Neurol Sci"},{"key":"13049_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00702-015-1470-9","volume":"123","author":"B Vesel\u00fd","year":"2016","unstructured":"Vesel\u00fd B, AntoniniRektor AI (2016) The contribution of white matter lesions to Parkinson\u2019s disease motor and gait symptoms: a critical review of the literature. J Neural Transm Vienna Austria 123:241\u2013250. https:\/\/doi.org\/10.1007\/s00702-015-1470-9","journal-title":"J Neural Transm Vienna Austria"},{"key":"13049_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107121","volume":"128","author":"X Kang","year":"2024","unstructured":"Kang X, Jiao T, Tan B et al (2024) Vascular disease and risk of fall-related injuries in Parkinson\u2019s disease: a nationwide cohort study in Sweden. Parkinsonism Relat Disord 128:107121. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107121","journal-title":"Parkinsonism Relat Disord"},{"key":"13049_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/mdc3.13504","volume":"9","author":"B Meira","year":"2022","unstructured":"Meira B, Fernandes M, Salavisa M et al (2022) Obstructive sleep apnea and other vascular risk factors\u2019 impact on non-motor symptoms in Parkinson\u2019s Disease. Mov Disord Clin Pract 9:785\u2013798. https:\/\/doi.org\/10.1002\/mdc3.13504","journal-title":"Mov Disord Clin Pract"},{"key":"13049_CR32","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/mds.26698","volume":"31","author":"N Malek","year":"2016","unstructured":"Malek N, Lawton MA, Swallow DMA et al (2016) Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 31:1518\u20131526. https:\/\/doi.org\/10.1002\/mds.26698","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"13049_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000161560","volume":"26","author":"GG Kovacs","year":"2008","unstructured":"Kovacs GG, Alafuzoff I, Al-Sarraj S et al (2008) Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 26:343\u2013350. https:\/\/doi.org\/10.1159\/000161560","journal-title":"Dement Geriatr Cogn Disord"},{"key":"13049_CR34","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/brain\/awad059","volume":"146","author":"JL Robinson","year":"2023","unstructured":"Robinson JL, Xie SX, Baer DR et al (2023) Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. Brain J Neurol 146:2557\u20132569. https:\/\/doi.org\/10.1093\/brain\/awad059","journal-title":"Brain J Neurol"},{"key":"13049_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.parkreldis.2014.02.012","volume":"20","author":"BN Dugger","year":"2014","unstructured":"Dugger BN, Adler CH, Shill HA et al (2014) Concomitant pathologies among a spectrum of Parkinsonian disorders. Parkinsonism Relat Disord 20:525\u2013529. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.02.012","journal-title":"Parkinsonism Relat Disord"},{"key":"13049_CR36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/brain\/awad388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu Y, Hirst WD, Federoff HJ et al (2024) Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease. Brain J Neurol 147:444\u2013457. https:\/\/doi.org\/10.1093\/brain\/awad388","journal-title":"Brain J Neurol"},{"key":"13049_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bpa.12182","volume":"25","author":"DR Howlett","year":"2015","unstructured":"Howlett DR, Whitfield D, Johnson M et al (2015) Regional multiple pathology scores are associated with cognitive decline in lewy body dementias. Brain Pathol Zurich Switz 25:401\u2013408. https:\/\/doi.org\/10.1111\/bpa.12182","journal-title":"Brain Pathol Zurich Switz"},{"key":"13049_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D et al (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16:55\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(16)30291-5","journal-title":"Lancet Neurol"},{"key":"13049_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/medicina59020294","volume":"59","author":"A Bougea","year":"2023","unstructured":"Bougea A, Papagiannakis N, Simitsi A-M et al (2023) Ambiental factors in Parkinson\u2019s disease progression: a systematic review. Med Kaunas Lith 59:294. https:\/\/doi.org\/10.3390\/medicina59020294","journal-title":"Med Kaunas Lith"},{"key":"13049_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.expneurol.2017.10.002","volume":"298","author":"J Blesa","year":"2017","unstructured":"Blesa J, Trigo-Damas I, Dileone M et al (2017) Compensatory mechanisms in Parkinson\u2019s disease: circuits adaptations and role in disease modification. Exp Neurol 298:148\u2013161. https:\/\/doi.org\/10.1016\/j.expneurol.2017.10.002","journal-title":"Exp Neurol"},{"key":"13049_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/mds.29266","volume":"38","author":"MC Hoenig","year":"2023","unstructured":"Hoenig MC, Dzialas V, Drzezga A, van Eimeren T (2023) The concept of motor reserve in Parkinson\u2019s disease: new wine in old bottles? Mov Disord Off J Mov Disord Soc 38:16\u201320. https:\/\/doi.org\/10.1002\/mds.29266","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"13049_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ana.26897","volume":"95","author":"SA Sakowski","year":"2024","unstructured":"Sakowski SA, Koubek EJ, Chen KS et al (2024) Role of the exposome in neurodegenerative disease: recent insights and future directions. Ann Neurol 95:635\u2013652. https:\/\/doi.org\/10.1002\/ana.26897","journal-title":"Ann Neurol"},{"issue":"1","key":"13049_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/09727531221136349","volume":"30","author":"S Kharel","year":"2023","unstructured":"Kharel S, Ojha R (2023) Future of monoclonal antibody therapy in Parkinson\u2019s disease. Ann Neurosci 30(1):8\u201310","journal-title":"Ann Neurosci"},{"issue":"2","key":"13049_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jamaneurol.2022","volume":"80","author":"AJ Espay","year":"2023","unstructured":"Espay AJ, Okun MS (2023) Abandoning the proteinopathy paradigm in Parkinson disease. JAMA Neurol 80(2):123\u2013124. https:\/\/doi.org\/10.1001\/jamaneurol.2022","journal-title":"JAMA Neurol"},{"key":"13049_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","volume":"92","author":"AJ Espay","year":"2019","unstructured":"Espay AJ, Vizcarra JA, Marsili L et al (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 92:329\u2013337. https:\/\/doi.org\/10.1212\/WNL.0000000000006926","journal-title":"Neurology"},{"key":"13049_CR46","doi-asserted-by":"publisher","first-page":"107256","DOI":"10.1016\/j.parkreldis.2024.107256","volume":"131","author":"AJ Espay","year":"2025","unstructured":"Espay AJ, Lees AJ, Cardoso F et al (2025) The \u03b1-synuclein seed amplification assay: Interpreting a test of Parkinson\u2019s pathology. Parkinsonism Relat Disord 131:107256. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107256","journal-title":"Parkinsonism Relat Disord"},{"key":"13049_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00109-6","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C (2023) Parkinson\u2019s progression markers initiative assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"key":"13049_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/mds.30085","volume":"40","author":"P Grillo","year":"2025","unstructured":"Grillo P, Concha-Marambio L, Pisani A et al (2025) Association between the amplification parameters of the \u03b1-synuclein seed amplification assay and clinical and genetic subtypes of Parkinson\u2019s disease. Mov Disord 40:305\u2013314. https:\/\/doi.org\/10.1002\/mds.30085","journal-title":"Mov Disord"},{"key":"13049_CR49","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J et al (2024) Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med 30:1096\u20131103. https:\/\/doi.org\/10.1038\/s41591-024-02886-y","journal-title":"Nat Med"},{"key":"13049_CR50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202867","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, L\u00f3pez-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D\u2019Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga \u0160, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A, PASADENA Investigators, Prasinezumab Study Group (2022) Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2202867","journal-title":"N Engl J Med"},{"key":"13049_CR51","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mds.29708","volume":"39","author":"C Marras","year":"2024","unstructured":"Marras C, Fereshtehnejad S-M, Berg D et al (2024) Transitioning from subtyping to precision medicine in Parkinson\u2019s disease: a purpose-driven approach. Mov Disord Off J Mov Disord Soc 39:462\u2013471. https:\/\/doi.org\/10.1002\/mds.29708","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"2","key":"13049_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JPD-202472","volume":"11","author":"TA Mestre","year":"2021","unstructured":"Mestre TA, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodr\u00edguez-Violante M, Simuni T, Surmeier DJ, Weintraub D, McDermott MP, Lawton M, Marras C (2021) Parkinson\u2019s disease subtypes: critical appraisal and recommendations. J Parkinsons Dis 11(2):395\u2013404. https:\/\/doi.org\/10.3233\/JPD-202472","journal-title":"J Parkinsons Dis"},{"key":"13049_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/mds.27867","volume":"35","author":"DG Coughlin","year":"2020","unstructured":"Coughlin DG, Hurtig HI, Irwin DJ (2020) Pathological influences on clinical heterogeneity in lewy body diseases. Mov Disord Off J Mov Disord Soc 35:5\u201319. https:\/\/doi.org\/10.1002\/mds.27867","journal-title":"Mov Disord Off J Mov Disord Soc"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13049-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T06:09:57Z","timestamp":1744956597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13049-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["13049"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13049-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"318"}}